New drug shows promise for Long-Term nasal polyp control
NCT ID NCT07424144
First seen Feb 21, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study looks at the long-term safety of a drug called itepekimab for adults with chronic sinusitis and nasal polyps that are hard to control. Participants who finished a previous itepekimab study can join and will receive either a high or low dose of the drug for up to 52 weeks, with 20 more weeks of follow-up. The goal is to see if the drug remains safe and helps keep symptoms under control over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 0362001
Spearwood, Western Australia, 6163, Australia
-
Investigational Site Number : 1521002
Santiago, Reg Metropolitana de Santiago, 7500692, Chile
-
Investigational Site Number : 1522003
Santiago, Reg Metropolitana de Santiago, 7500505, Chile
-
Investigational Site Number : 1562001
Beijing, 100730, China
-
Investigational Site Number : 1562004
Chengdu, 610017, China
-
Investigational Site Number : 1562008
Jingzhou, 434020, China
-
Investigational Site Number : 4101001
Seoul, Seoul-teukbyeolsi, 07061, South Korea
-
Investigational Site Number : 8261004
Bradford, BD9 6RJ, United Kingdom
-
Investigational Site Number : 8262002
Wigan, Lancashire, Wn6 9ep, United Kingdom
-
Velocity Clinical Research - San Diego- Site Number : 8402041
La Mesa, California, 91942, United States
Conditions
Explore the condition pages connected to this study.